Show simple item record

dc.contributor.authorMendiguren Ordorica, Aitziber
dc.contributor.authorAostri Parga, Erik ORCID
dc.contributor.authorRodilla Ojeda, Irati ORCID
dc.contributor.authorPujana, Iker
dc.contributor.authorNoskova, Ekaterina
dc.contributor.authorPineda Ortiz, Joseba Gotzon ORCID
dc.date.accessioned2023-07-05T17:19:31Z
dc.date.available2023-07-05T17:19:31Z
dc.date.issued2023-05
dc.identifier.citationFrontiers in Pharmacology 14 : (2023) // Article ID 1183019es_ES
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/10810/61896
dc.description.abstractThe pharmacological profile of cannabigerol (CBG), which acid form constitutes the main precursor of the most abundant cannabinoids, has been scarcely studied. It has been reported to target α2-adrenoceptor and 5-HT1A receptor. The locus coeruleus (LC) and the dorsal raphe nucleus (DRN) are the main serotonergic (5-HT) and noradrenergic (NA) areas in the rat brain, respectively. We aimed to study the effect of CBG on the firing rate of LC NA cells and DRN 5-HT cells and on α2-adrenergic and 5-HT1A autoreceptors by electrophysiological techniques in male Sprague-Dawley rat brain slices. The effect of CBG on the novelty-suppressed feeding test (NSFT) and the elevated plus maze test (EPMT) and the involvement of the 5-HT1A receptor was also studied. CBG (30 μM, 10 min) slightly changed the firing rate of NA cells but failed to alter the inhibitory effect of NA (1–100 µM). However, in the presence of CBG the inhibitory effect of the selective α2-adrenoceptor agonist UK14304 (10 nM) was decreased. Perfusion with CBG (30 μM, 10 min) did not change the firing rate of DRN 5-HT cells or the inhibitory effect of 5-HT (100 μM, 1 min) but it reduced the inhibitory effect of ipsapirone (100 nM). CBG failed to reverse ipsapirone-induced inhibition whereas perfusion with the 5-HT1A receptor antagonist WAY100635 (30 nM) completely restored the firing rate of DRN 5-HT cells. In the EPMT, CBG (10 mg/kg, i.p.) significantly increased the percentage of time the rats spent on the open arms and the number of head-dipping but it reduced the anxiety index. In the NSFT, CBG decreased the time latency to eat in the novel environment but it did not alter home-cage consumption. The effect of CBG on the reduction of latency to feed was prevented by pretreatment with WAY100635 (1 mg/kg, i.p.). In conclusion, CBG hinders the inhibitory effect produced by selective α2-adrenoceptor and 5-HT1A receptor agonists on the firing rate of NA-LC and 5-HT-DRN neurons by a yet unknown indirect mechanism in rat brain slices and produces anxiolytic-like effects through 5-HT1A receptor.es_ES
dc.description.sponsorshipThis work was supported by the Ministerio de Sanidad, Consumo y Bienestar Social. Delegación del Gobierno para el Plan Nacional Sobre Drogas, PND 2018I025, (PND18/04) and University of the Basque Country (UPV/EHU) (Grant GIU19/076). EA and IR were supported by a predoctoral fellowship from the Basque and Spanish Government, respectively.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectdorsal raphe nucleuses_ES
dc.subjectslicees_ES
dc.subjectfiringes_ES
dc.subjectnoradrenalinees_ES
dc.subjectlocus coeruleuses_ES
dc.subjectcannabigeroles_ES
dc.subjectanxiety, serotonines_ES
dc.titleCannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rates_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2023 Mendiguren, Aostri, Rodilla, Pujana, Noskova and Pineda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fphar.2023.1183019/fulles_ES
dc.identifier.doi10.3389/fphar.2023.1183019
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuFarmakologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2023 Mendiguren, Aostri, Rodilla, Pujana, Noskova and Pineda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as © 2023 Mendiguren, Aostri, Rodilla, Pujana, Noskova and Pineda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.